X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (504) 504
Publication (64) 64
Book Review (6) 6
Book Chapter (3) 3
Book / eBook (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Patent (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (323) 323
female (299) 299
oncology (272) 272
breast cancer (210) 210
breast neoplasms - drug therapy (181) 181
middle aged (181) 181
adult (159) 159
index medicus (155) 155
aged (137) 137
chemotherapy (128) 128
breast neoplasms - pathology (126) 126
chemotherapy, adjuvant (104) 104
cancer (97) 97
antineoplastic combined chemotherapy protocols - therapeutic use (94) 94
prognosis (86) 86
disease-free survival (83) 83
treatment outcome (82) 82
therapy (81) 81
breast neoplasms - mortality (71) 71
tamoxifen (69) 69
breast neoplasms - surgery (63) 63
hematology, oncology and palliative medicine (62) 62
antineoplastic agents, hormonal - therapeutic use (58) 58
breast neoplasms - therapy (53) 53
care and treatment (53) 53
clinical trials (52) 52
breast neoplasms - metabolism (48) 48
tamoxifen - therapeutic use (46) 46
lymphatic metastasis (45) 45
neoplasm staging (45) 45
postmenopausal women (45) 45
research (45) 45
survival (42) 42
follow-up studies (41) 41
women (41) 41
adjuvant treatment (39) 39
medicine & public health (38) 38
aged, 80 and over (37) 37
combined modality therapy (36) 36
cyclophosphamide - administration & dosage (36) 36
estrogen (36) 36
medicine, general & internal (36) 36
receptors, estrogen - metabolism (36) 36
cyclophosphamide (35) 35
drug therapy (35) 35
fluorouracil - administration & dosage (35) 35
survival analysis (35) 35
health aspects (34) 34
surgery (34) 34
trastuzumab (34) 34
retrospective studies (33) 33
risk factors (33) 33
analysis (32) 32
carcinoma (32) 32
endocrine therapy (32) 32
obstetrics & gynecology (32) 32
quality of life (32) 32
article (31) 31
drug administration schedule (31) 31
postmenopause (31) 31
adjuvant chemotherapy (30) 30
antineoplastic agents - therapeutic use (30) 30
male (30) 30
mastectomy (30) 30
antineoplastic combined chemotherapy protocols - administration & dosage (29) 29
cancer patients (29) 29
randomized controlled trials as topic (29) 29
receptor, erbb-2 - metabolism (29) 29
receptors, estrogen - analysis (29) 29
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
randomized-trial (28) 28
survival rate (28) 28
tamoxifen - administration & dosage (28) 28
breast neoplasms - genetics (26) 26
immunohistochemistry (26) 26
methotrexate - administration & dosage (26) 26
clinical trials as topic (25) 25
oncology, experimental (25) 25
premenopause (25) 25
proportional hazards models (25) 25
kaplan-meier estimate (24) 24
menopause (24) 24
antineoplastic agents, hormonal - adverse effects (23) 23
breast neoplasms - chemistry (23) 23
methotrexate (23) 23
trial (23) 23
tumors (23) 23
cancer therapies (22) 22
tamoxifen - adverse effects (21) 21
antineoplastic agents - adverse effects (20) 20
receptors, progesterone - metabolism (20) 20
nitriles - therapeutic use (19) 19
radiotherapy (19) 19
triazoles - therapeutic use (19) 19
adjuvant therapy (18) 18
antineoplastic agents (18) 18
breast neoplasms (18) 18
fluorouracil (18) 18
letrozole (18) 18
metastasis (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, 09/2002, Volume 38, Issue 14, pp. 1814 - 1814
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 4, pp. 297 - 305
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Journal Article
1990, Monographs / European School of Oncology., ISBN 9780387529615, 97
Book
Breast, The, ISSN 0960-9776, 2013, Volume 22, pp. S3 - S7
Abstract For several decades, personalized adjuvant therapies have been prescribed based on features that predict response to specific types of treatment. In... 
Hematology, Oncology and Palliative Medicine | Primary Breast Cancer | St. Gallen Breast Cancer Consensus | Breast Cancer: Optimal Primary Therapy | Breast Cancer Treatment Guidelines | Chemotherapy | Postmenopausal women | Tamoxifen | Steroid hormones | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 737 - 746
Despite the acknowledged sex-related dimorphism in immune system response, little is known about the effect of patients' sex on the efficacy of immune... 
CELL LUNG-CANCER | PHASE-III TRIAL | CHECKPOINT INHIBITORS | ONCOLOGY | ADVANCED MELANOMA | DOUBLE-BLIND | GENDER | NIVOLUMAB | T-CELLS | IPILIMUMAB | CHEMOTHERAPY | Cancer patients | Care and treatment | Analysis | Immunotherapy | Metastasis | Drug therapy | Lung cancer, Non-small cell | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 08/2014, Volume 11, Issue 8, p. 443
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Journal Article